New trial
A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma
- Trial ID
- NCT04005690 on ClinicalTrials.gov
- Cancer type
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Published in
- New in Oncology - May 21, 2025
This early phase I trial from OHSU is investigating multiple targeted agents (cobimetinib, olaparib, onvansertib, azenosertib, AZD5305, and tremelimumab) in advanced pancreatic cancer through pre- and post-treatment biopsies to validate molecular targets for future biomarker-driven studies, with enrollment in Portland.
More in pancreatic cancer
-
Trial result · Oct 15, 2026 · NCT04543071
Motixafortide (CXCR4 inhibitor) + cemiplimab (PD-1) + gem/nab-paclitaxel posts 55% confirmed ORR in 1L metastatic PDAC -
Trial result · Oct 15, 2026 · NCT06850623
ACT (PS101 + focused ultrasound) plus mFOLFIRINOX shows early responses and a resection conversion signal in locally advanced/borderline PDAC -
Trial result · Oct 15, 2026 · NCT07562152
Atebimetinib (deep cyclic MEK inhibitor) + mGnP links weight preservation to longer OS in 1L pancreatic cancer -
New trial · Oct 15, 2026 · NCT07619521
Phase 1/2 selumetinib plus trastuzumab deruxtecan targets KRAS-mutant, HER2-expressing pancreatic cancer -
New trial · Oct 15, 2026 · NCT07824960
Phase 1b/2 avutometinib plus defactinib adds RAF/MEK and FAK inhibition to mFOLFIRINOX in pancreatic cancer